United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $497.54, for a total value of $4,129,582.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $22,474,876.88. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $494.63 on Friday. United Therapeutics Corporation has a 1 year low of $408.75 and a 1 year high of $609.35. The company has a market capitalization of $21.21 billion, a PE ratio of 17.70, a price-to-earnings-growth ratio of 2.49 and a beta of 0.56. The business has a fifty day moving average price of $515.48 and a two-hundred day moving average price of $540.32.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the business posted $6.41 EPS. Sell-side analysts anticipate that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. BlackRock Inc. bought a new stake in shares of United Therapeutics during the 2nd quarter worth $2,868,735,000. Janus Henderson Group PLC increased its stake in United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares during the last quarter. Jupiter Topco LLC bought a new position in United Therapeutics in the second quarter valued at $450,140,000. Norges Bank purchased a new stake in United Therapeutics during the fourth quarter valued at about $293,418,000. Finally, Swedbank AB raised its position in United Therapeutics by 0.7% during the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock valued at $193,977,000 after purchasing an additional 2,350 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Bank of America reduced their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Royal Bank Of Canada decreased their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. JPMorgan Chase & Co. upped their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Finally, Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.